<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Xeroderma pigmentosum</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Xeroderma pigmentosum</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Xeroderma pigmentosum</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laura J Niedernhofer, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christina L Boull, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheilagh M Maguiness, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth L Thompson, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer L Hand, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3333079355"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Xeroderma pigmentosum (XP) is a rare, autosomal recessive disorder caused by defective nucleotide excision repair (NER), most notably of ultraviolet (UV)-induced deoxyribonucleic acid (DNA) helix-distorting lesions. Most individuals with XP experience a very high rate of skin cancer beginning early in life. Additional features are associated with different variants associated with specific genes. A subset of patients, associated with certain genetic variants, develop progressive neurologic deterioration, vision and hearing loss, and internal malignancies.</p><p>This topic will discuss the pathogenesis, clinical manifestations, diagnosis, and management of XP. Other disorders associated with increased photosensitivity are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7101.html" rel="external">"Porphyrias: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15510.html" rel="external">"Kindler epidermolysis bullosa"</a>.)</p><p></p><p class="headingAnchor" id="H1750066924"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The prevalence of XP is estimated to be approximately 1:1,000,000 in the United States and Europe and 1:22,000 in Japan [<a href="#rid1">1,2</a>]. A founder <em>XPA</em> gene variant with a frequency of 1 percent in Japan accounts for the higher prevalence of XP in Japan [<a href="#rid2">2</a>]. Increased incidence is observed in some Asian and African countries, including <strong>Bangladesh, Somalia </strong>[<a href="#rid3">3</a>]<strong>,</strong> Pakistan [<a href="#rid4">4</a>], Egypt [<a href="#rid5">5</a>], Tunisia [<a href="#rid6">6</a>], and Morocco [<a href="#rid7">7</a>], <strong>possibly due to more frequent consanguinity.</strong></p><p class="headingAnchor" id="H1045945203"><span class="h1">MOLECULAR GENETICS AND PATHOGENESIS</span><span class="headingEndMark"> — </span>The eight genes (complementation groups) involved in the pathogenesis of XP are associated with either the repair (<em>XPA</em>, <em>XPB</em>, <em>XPC</em>, <em>XPD</em>, <em>XPE</em>, <em>XPF</em>, and <em>XPG</em>) or the tolerance (XP variant [<em>XPV</em>]) of ultraviolet (UV)-induced DNA damage and other DNA helix-distorting lesions [<a href="#rid8">8-10</a>]. Before specific variants were identified using molecular technology, incubation of an affected individual's cells could be restored to normal function using cells from an individual with a different variant, establishing complementation groups. Complementation group is now known to refer to the gene in which the variant occurs. Individuals with different variants within the same gene would share the same complementation group.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nucleotide excision repair</strong> – The most common forms of UV-induced DNA damage are cyclobutane pyrimidine dimers and 6-4 photoproducts, and both DNA lesions are repaired by nucleotide excision repair (NER). The NER pathway is initiated through either global genome nucleotide excision repair (GG-NER) or transcription-coupled nucleotide excision repair (TC-NER).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>GG-NER involves the function of two XP-associated proteins (XPC and XPE) that continuously probe DNA and recognize bulky adducts based on DNA helical distortion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alternatively, TC-NER is initiated by the stalling of ribonucleic acid (RNA) polymerase II during transcription due to a DNA lesion, leading to recruitment of the proteins associated with Cockayne syndrome types A and B to the site of DNA damage.</p><p></p><p class="bulletIndent1">Both the GG-NER and TC-NER pathways then converge on the same repair mechanism with the recruitment of the transcription factor II H complex. The transcription factor II H complex contains two helicase subunits (XPB and XPD) that unwind DNA in opposite directions to expose the damaged DNA strand. XPA is involved in confirming the presence of a DNA lesion and recruiting downstream repair factors.</p><p></p><p class="bulletIndent1">The endonucleases that remove the damaged patch of DNA are the heterodimer XPF-ERCC1 that cleaves 5' of the lesion and XPG that cleaves 3', releasing a single-stranded oligonucleotide containing the DNA adduct. These endonucleases create a 20 to 30 nucleotide gap in one strand of the DNA double helix that is filled in by the replication machinery: a DNA polymerase for templated DNA synthesis and DNA ligases to restore the integrity of the DNA phosphodiester backbone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DNA translesion synthesis</strong> – Uniquely, XPV is not an NER protein but a DNA polymerase involved in DNA damage tolerance via translesion synthesis (TLS). XPV can replicate DNA across a UV-induced lesion, allowing replication to continue without repair, albeit often at the price of creating a mutation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genotype/phenotype correlations</strong> – The broad clinical heterogeneity of XP can be attributed to the function of the affected gene (complementation group) in the NER pathway, additional functions of the gene product in other DNA repair pathways, and the effect of the mutation on gene function or expression [<a href="#rid3">3,11</a>]. The largest impact on disease severity is determined by whether the affected protein functions in GG-NER, TC-NER, or TLS [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Variants in genes associated with GG-NER (<em>XPC</em> and <em>XPE</em>) typically result in milder phenotypes and normal sunburn reaction. However, GG-NER defects are associated with high mutation rates and increased cancer risk.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Variants in genes associated with TC-NER (<em>XPA</em>, <em>XPB</em>, <em>XPD</em>, <em>XPF</em>, and <em>XPG</em>) are often associated with more severe phenotypes, with systemic symptoms including neurodegeneration. Unrepaired oxidative DNA damage within neurons, leading to cell death and progressive cerebral atrophy, is the mechanism of neurologic degeneration [<a href="#rid12">12-14</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some NER proteins have additional functions in other DNA repair pathways. Thus, defective proteins result in symptoms overlapping with those of other genome instability disorders (eg, Fanconi anemia or Cockayne syndrome)  (<a class="graphic graphic_table graphicRef142535" href="/z/d/graphic/142535.html" rel="external">table 1</a>) [<a href="#rid8">8,13</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TLS (<em>XPV</em>) variants are associated with a milder phenotype, normal sunburn reaction, but increased risk of skin cancer later in life.</p><p></p><p class="headingAnchor" id="H3427217070"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>All patients with XP experience photosensitivity and increased rates of skin cancer. The degree of photosensitivity and neurologic compromise vary by complementation group and the severity of the pathogenic variant (eg, missense variant versus stop codon).</p><p class="headingAnchor" id="H1071082386"><span class="h2">Early skin findings</span><span class="headingEndMark"> — </span>With the exception of complementation groups XPE and XPV, the skin manifestations associated with XP typically appear in early childhood and worsen over time.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lentigines and freckles</strong> – Children with XPC present initially with lentigines and freckles in sun-exposed areas, typically by age two  (<a class="graphic graphic_picture graphicRef117861" href="/z/d/graphic/117861.html" rel="external">picture 1</a>) [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sunburn</strong> – Sunburns may be severe, prolonged, and blistering, even with minimal sun exposure [<a href="#rid16">16</a>]. Complementation groups with exaggerated sunburn reactions include XPA, XPB, XPD, XPF, and XPG [<a href="#rid3">3</a>]. In contrast, patients with XPC, XPE, and XPV have more normal reactions to sun exposure, which delays XP diagnosis. They may not come to medical attention until early adulthood, often with a high skin cancer burden [<a href="#rid15">15</a>]. (See <a class="local">'Skin cancer'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pigmentary changes</strong> – Over time, the skin develops progressive mottling with hyper- and hypopigmentation and scaling papules.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Premature aging</strong> – Patients with XP show signs of premature aging of the skin with increasing number of lentigines on the skin and lips, telangiectasias, poikiloderma, xerosis, skin atrophy, and wrinkling  (<a class="graphic graphic_picture graphicRef142536 graphicRef142537 graphicRef142538" href="/z/d/graphic/142536.html" rel="external">picture 2A-C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Actinic keratoses and nonmelanoma skin cancers</strong> – Actinic keratoses and nonmelanoma skin cancers may develop in the first decade of life [<a href="#rid15">15</a>]. (See <a class="local">'Skin cancer'</a> below.)</p><p></p><p class="headingAnchor" id="H2799091988"><span class="h2">Skin cancer</span><span class="headingEndMark"> — </span>Skin cancer is a leading source of morbidity and mortality in XP. The most common cutaneous malignancies are nonmelanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma  (<a class="graphic graphic_picture graphicRef118368" href="/z/d/graphic/118368.html" rel="external">picture 3</a>). Patients with XP have &gt;10,000 times higher risk of nonmelanoma skin cancer and &gt;2000 times higher risk of melanoma compared with the general population. Patients with XP develop their first nonmelanoma skin cancer and melanoma at a median age of 9 and 22 years, respectively, decades earlier than individuals without XP [<a href="#rid11">11</a>]. Skin cancers occur exclusively on exposed areas of the body.</p><p></p><p class="headingAnchor" id="H634607574"><span class="h2">Oral cancers</span><span class="headingEndMark"> — </span>Patients with XP may develop tongue cancer at a very young age [<a href="#rid17">17,18</a>]. Tongue tip and dorsal tongue (presumably sun-exposed areas) are the most common sites. Cancers of the gingiva and palate as well as oral angiosarcoma and fibrosarcoma have also been reported in patients with XP [<a href="#rid19">19,20</a>]. Intraoral pyogenic granulomas are also more common in patients with XP than in individuals without XP and may mimic oral malignancies [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/13736.html" rel="external">"Pyogenic granuloma (lobular capillary hemangioma)"</a>.)</p><p class="headingAnchor" id="H2914656101"><span class="h2">Ocular findings</span><span class="headingEndMark"> — </span>Ultraviolet (UV) injury causes ocular abnormalities in over 90 percent of patients with XP [<a href="#rid22">22</a>]. These include photophobia (most common), conjunctival injection, corneal neovascularization and scarring, ectropion, conjunctival melanosis, and ocular surface cancers [<a href="#rid22">22,23</a>]. Patients with XPC have the most severe ocular disease [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H734285313"><span class="h2">Neurologic findings</span><span class="headingEndMark"> — </span>Up to approximately 40 percent of patients with XP, depending on type, experience neurodegeneration with progressive cognitive decline, sensorineural hearing loss, peripheral neuropathy, ataxia, and loss of speech [<a href="#rid11">11,24,25</a>]. High-frequency hearing loss and loss of deep tendon reflexes are the first signs of neurologic deterioration and begin at approximately two years of age in the most severe cases [<a href="#rid9">9</a>].</p><p>Neurologic manifestations are most common in XPA and XPD. They are also seen in XPB, XPF, and XPG [<a href="#rid12">12,13</a>] but not in XPC, XPE, or XPV [<a href="#rid26">26</a>]. Although patients with XPC do not have progressive neurodegeneration, hearing loss has been reported [<a href="#rid3">3,24,26</a>].</p><p class="headingAnchor" id="H2831078558"><span class="h2">Associated internal malignancies</span><span class="headingEndMark"> — </span>Patients with certain XP types have a 10 to 35 times higher risk of developing internal malignancies compared with the general population [<a href="#rid27">27-30</a>]. Moreover, malignancies occur in these patients at a much younger age. Patients with XPC are at the highest risk. Hematologic cancers (eg, myelodysplastic syndrome, acute lymphoblastic leukemia, acute myeloid leukemia, lymphoma) and central nervous system malignancies (eg, glioblastoma, medulloblastoma, astrocytoma, schwannoma) are most common [<a href="#rid30">30,31</a>]. Other associated cancers include thyroid, gynecologic (ovarian, uterine), breast, esophageal, gastric, prostate, and renal cancers [<a href="#rid11">11,30,32</a>]. Colorectal and lung cancers have also been reported in patients with XPG and XPD, respectively [<a href="#rid33">33,34</a>]. Early-onset thyroid nodules have been noted in patients with XP [<a href="#rid35">35</a>]. While risk of malignant transformation is low, surveillance for thyroid abnormalities is warranted in patients with XP.</p><p class="headingAnchor" id="H3971763092"><span class="h2">Reproductive concerns</span><span class="headingEndMark"> — </span>Female patients with XP are more likely to experience premature menopause [<a href="#rid36">36</a>]. In a study of female patients with XP who were followed at the National Institutes of Health, menarche occurred at a median age of 12, consistent with norms in the general population, but menopause was experienced at a median age of 29.5 years. Of the 60 females in the study, 21 gave birth to a total of 32 children. Further investigation is needed to determine the full impact of XP on reproductive health in males and females.</p><p class="headingAnchor" id="H1562601536"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H562754758"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>The rarity of XP coupled with the variable clinical presentation often results in a delayed diagnosis or even investigation for child abuse. XP should be suspected in children presenting with one or more of the following [<a href="#rid37">37,38</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe sun sensitivity on minimal exposure</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early skin freckling (before the age of two years)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin cancer during childhood</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ocular symptoms (eg, photophobia with marked conjunctival injection, keratitis, corneal neovascularization and scarring)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic symptoms (eg, loss of deep tendon reflexes, hearing loss)</p><p></p><p>XP should also be suspected in young adult patients with multiple skin cancers in the absence of increased sun sensitivity. Patients with XPE and XPV may in fact not come to medical attention until early adulthood, often with a high skin cancer burden.</p><p class="headingAnchor" id="H2366547857"><span class="h2">Unscheduled DNA synthesis</span><span class="headingEndMark"> — </span>The measurement of unscheduled DNA synthesis (UDS) following ultraviolet (UV) irradiation of live cells (historically dermal fibroblasts) from patients suspected to have XP is the pathognomonic diagnostic test for XP [<a href="#rid39">39,40</a>]. DNA synthesis outside of the S phase of the cell cycle (ie, UDS) that occurs in those cells following UV irradiation is, by definition, nucleotide excision repair (NER). With the exception of XPV, this assay is agnostic to the complementation group but provides information about the impact of inherited pathogenic variants on a patient's NER capacity. UV-induced UDS can range from undetectable to normal and roughly correlates with disease severity. Unlike the other complementation groups, XPV has normal levels of UDS and NER because XPV is involved in UV-induced DNA damage tolerance rather than repair.</p><p>Measuring UDS requires establishing primary cell cultures, typically from a skin biopsy, which is not routinely available in Clinical Laboratory Improvement Amendments (CLIA)-certified diagnostic laboratories.</p><p class="headingAnchor" id="H171768042"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>Genetic testing is more widely available than UDS for the diagnosis of XP. Options include serial single-gene testing, multigene panels, or complete genomic testing. Targeted, multigene panels that test for several XP variants have higher sensitivity than single gene tests and are therefore preferred. The finding of biallelic pathogenic variants in one of the genes involved in XP confirms the diagnosis [<a href="#rid37">37</a>].</p><p>The detection of novel variants not previously reported requires further testing, usually performed in research settings, to determine their impact on NER capacity.</p><p>In cases where the clinical suspicion is high but targeted testing is negative, whole exome sequencing can be performed. Whole exome sequencing can detect other genetic diseases with clinical presentations similar to XP. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H1080035405"><span class="h2">Prenatal testing</span><span class="headingEndMark"> — </span>Prenatal genetic testing through chorionic villus sampling or amniocentesis can be offered to families with known XP pathogenic variants [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H2633125904"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genome instability disorders associated with photosensitivity</strong> – Genome instability disorders related to XP include, among others, Cockayne syndrome, trichothiodystrophy, and ultraviolet (UV)-sensitive syndrome  (<a class="graphic graphic_table graphicRef117627" href="/z/d/graphic/117627.html" rel="external">table 2</a>). They share features with XP, including increased photosensitivity, but are not associated with an increased risk of malignancy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cockayne syndrome</strong> – Cockayne syndrome is a rare genetic disorder caused by biallelic variants in the <em>CSA</em> and <em>CSB</em> genes [<a href="#rid42">42</a>]. Patients with Cockayne syndrome have characteristic bird-like facies; global developmental delay; and a spectrum of progressive, neurologic abnormalities [<a href="#rid43">43,44</a>]. An XP-Cockayne syndrome overlap syndrome has been described [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/6226.html" rel="external">"Neuropathies associated with hereditary disorders", section on 'Cockayne syndrome'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Trichothiodystrophy</strong> – Trichothiodystrophy is a rare, genetically heterogeneous, autosomal recessive disorder. Photosensitive trichothiodystrophy (types 1, 2, and 3) is caused by biallelic variants in <em>ERCC2</em>, <em>ERCC3</em>, and<em> GTF2H5</em>. Patients with trichothiodystrophy present with neurologic and developmental abnormalities, brittle hair  (<a class="graphic graphic_picture graphicRef87474" href="/z/d/graphic/87474.html" rel="external">picture 4</a>), and ichthyosiform skin changes [<a href="#rid46">46,47</a>]. Hairs show alternating birefringence ("tiger tail" appearance) when viewed with polarized light  (<a class="graphic graphic_picture graphicRef118338" href="/z/d/graphic/118338.html" rel="external">picture 5</a>). (See  <a class="medical medical_review" href="/z/d/html/112583.html" rel="external">"Autosomal recessive congenital ichthyoses", section on 'Trichothiodystrophy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>UV-sensitive syndrome</strong> – UV-sensitive syndrome is an autosomal recessive disorder of nucleotide excision repair (NER) caused by variants in the <em>ERCC6</em>, <em>ERCC8</em>, or <em>UVSSA</em> genes [<a href="#rid48">48</a>]. UV-sensitive syndrome is associated with mild photosensitivity, cutaneous hyperpigmentation, and freckling starting very early in life [<a href="#rid49">49</a>]. There is no known increased risk of cutaneous or internal malignancy or neurologic defects [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other inherited disorders associated with photosensitivity</strong> – Other rare, autosomal recessive disorders associated with photosensitivity may be differentiated from XP based on the clinical and genetic findings.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Erythropoietic protoporphyria</strong> – Erythropoietic protoporphyria (MIM #177000) is an autosomal recessive disorder caused by variants in <em>FECH</em>,<em> </em>resulting in reduced synthesis of ferrochelatase, an enzyme in the heme biosynthetic pathway [<a href="#rid51">51</a>]. Erythropoietic protoporphyria is characterized by the acute onset of nonblistering, painful erythema in sun-exposed areas. Anemia is present in approximately one-half of all patients. (See  <a class="medical medical_review" href="/z/d/html/7125.html" rel="external">"Erythropoietic protoporphyria and X-linked protoporphyria"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bloom syndrome</strong> – Bloom syndrome (MIM #210900) is a rare, autosomal recessive, chromosomal instability disorder caused by pathogenic variants in the <em>BLM</em> gene. Patients with Bloom syndrome are sun sensitive and develop facial erythema, telangiectasias, and atrophy of the central face in a butterfly distribution. UV-induced erythema and blistering can develop on any exposed body sites. Additional features include high-pitched voice; short stature; and long, narrow face with a prominent nose. Immunoglobulin deficiencies and malignancies, especially hematologic, are also common [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/z/d/html/3959.html" rel="external">"Bloom syndrome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rothmund-Thomson syndrome</strong> – Rothmund-Thomson syndrome is an autosomal recessive disorder caused by variants in <em>ANAPC1 </em>(MIM #618625) or <em>RECQL4</em> (MIM #268400). Rothmund-Thomson syndrome is characterized by facial erythema and blistering that develop in the first few months of life and progress to reticulate pigment changes, telangiectasias, and atrophy (poikiloderma)  (<a class="graphic graphic_picture graphicRef117575" href="/z/d/graphic/117575.html" rel="external">picture 6</a>) [<a href="#rid53">53</a>]. Other features include sparse hair, eyelashes, and eyebrows; skeletal/dental defects; cataracts; and increased cancer risk, especially osteosarcoma.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hartnup disease</strong> – Hartnup disease (MIM #234500) is an autosomal recessive disorder caused by variants in <em>SLC6A19</em>, resulting in decreased neutral amino acid absorption from the kidneys and intestinal tract [<a href="#rid54">54</a>]. Patients with Hartnup disease present with pellagra-like, scaling, pink patches in sun-exposed sites; cerebellar ataxia; and mild intellectual impairment.</p><p></p><p class="headingAnchor" id="H3729706303"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Patients with XP are best managed by a multidisciplinary team including dermatologists, ophthalmologists, audiologists, oral surgeons, geneticists, and neurologists. Strict sun protection and avoidance, close clinical follow-up with regular skin and eye examination, and appropriate and early management of any premalignant and malignant skin lesions are the mainstays of treatment.</p><p class="headingAnchor" id="H3746661543"><span class="h2">Prevention and early detection of skin cancer</span><span class="headingEndMark"> — </span>Implementation of strict ultraviolet (UV) protection and early detection and treatment of skin cancers and premalignant lesions are the mainstays of management of patients with XP.</p><p class="headingAnchor" id="H3125416798"><span class="h3">Photoprotection strategies</span><span class="headingEndMark"> — </span>Individuals with XP and their parents or caregivers should be educated about the importance of strict sun protection for the prevention of skin cancer and other cutaneous manifestations of XP. However, studies have shown that adherence to photoprotection is variable, and poor adherence may be a significant issue among patients with XP [<a href="#rid55">55</a>]. An international study investigating the psychologic correlates of photoprotection in 156 adult patients with XP found that face photoprotection was suboptimal in at least one-third of the patients [<a href="#rid56">56</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sun avoidance and sun protection</strong> – Sun exposure should be avoided. During daylight hours, protective garments, wide-brimmed hats attached to UV-protective face shields, sunglasses, and gloves are recommended. All skin should be covered with clothing made of UV-resistant fabric (see  <a class="medical medical_review" href="/z/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures", section on 'Photoprotective clothing'</a>). Layering of clothing enhances protection.</p><p></p><p class="bulletIndent1">Broad-spectrum sunscreen with a sun protection factor (SPF) of 30 or higher should be applied every two hours to sun-exposed areas. (See  <a class="medical medical_review" href="/z/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Creating</strong> <strong>ultraviolet-safe environments</strong> – UV-safe environments can be created by applying UV-resistant film to windows in the car, home, and school. Incandescent light bulbs with low wattage or light-emitting diode (LED) lights are safest. Fluorescent and halogen lights can be a source of UV exposure and should be shielded [<a href="#rid57">57</a>]. Handheld UV meters can help determine UV exposure risk and are useful for families to assess the safety of unfamiliar environments and when it is safe to go outdoors without head-to-toe barrier protection. Levels of under 2 to 3 microW/cm<sup>2</sup> are recommended, although safe levels are unknown.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of vitamin D deficiency</strong> – Patients with XP are at risk for vitamin D deficiency; supplementation is usually needed.</p><p></p><p class="headingAnchor" id="H998387570"><span class="h3">Chemoprevention</span><span class="headingEndMark"> — </span>In patients with XP, chemoprevention strategies aimed at reducing the development of actinic keratoses and cutaneous squamous cell carcinomas may be considered based on patients' characteristics and preferences. (See  <a class="medical medical_review" href="/z/d/html/128194.html" rel="external">"Cutaneous squamous cell carcinoma: Primary and secondary prevention", section on 'Chemoprevention'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical agents</strong> – Both topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> and <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> have been evaluated for the prevention of keratinocyte carcinomas in patients with multiple actinic keratoses and field cancerization [<a href="#rid58">58,59</a>]. However, evidence on their efficacy in patients with XP is limited to a few case reports.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Topical </strong><strong>fluorouracil</strong> – In two patients with XP, pulsed dosing of topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> every three months decreased the rates of new squamous cell carcinoma and basal cell carcinoma [<a href="#rid60">60</a>]. The primary side effect of topical fluorouracil is skin irritation at the sites of use.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Imiquimod</strong> – In a series of 15 patients with XP (8 with XPV) treated with <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> 5% applied to one cheek five times per week for six weeks, none developed a skin cancer on the treated area during a two-year follow-up time [<a href="#rid61">61</a>]. Adverse effects included local inflammation, ulceration, and crusting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic agents</strong> – Systemic agents that have been investigated for the prevention of keratinocyte carcinomas include oral retinoids and nicotinamide. The latter has not been tested in patients with XP.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High-dose oral </strong><strong>isotretinoin</strong> – In a study of five patients with XP, high-dose oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> 2 mg/kg per day for two years substantially decreased the number of new skin cancer development (from 121 in the two-year interval before starting treatment to 25 in the two years during treatment) [<a href="#rid62">62</a>]. However, a rebound in skin cancer frequency was noted after treatment discontinuation [<a href="#rid63">63</a>]. Adverse effects of high-dose isotretinoin limit its prolonged use. There is no evidence supporting the use of lower-dose regimens.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nicotinamide</strong> – Nicotinamide (vitamin B3) is an oral supplement that may prevent actinic keratoses and nonmelanoma skin cancers. In a trial randomizing high-risk individuals to either nicotinamide 500 mg twice daily or placebo, those receiving nicotinamide had a 23 percent reduction in the incidence of new nonmelanoma skin cancer and a 14 percent reduction in actinic keratoses at 12 months [<a href="#rid64">64</a>]. However, a subsequent study in transplant patients, also at increased risk of cutaneous malignancies in sun-exposed areas, failed to identify a significant reduction in nonmelanoma skin cancer at 12 months [<a href="#rid65">65</a>]. No serious side effects were noted in either study.</p><p></p><p class="headingAnchor" id="H3183922199"><span class="h3">Skin cancer surveillance</span><span class="headingEndMark"> — </span>Close clinical follow-up for early detection and treatment of skin cancer and premalignant lesions is indicated for all patients with XP. Most patients are seen for skin examinations at least twice yearly and more often if they have a history of skin cancer.</p><p class="headingAnchor" id="H3049318613"><span class="h2">Treatment of skin cancer and precursor lesions</span></p><p class="headingAnchor" id="H3454268466"><span class="h3">Actinic keratosis</span><span class="headingEndMark"> — </span>Prompt and frequent treatment of actinic keratoses is important to prevent progression to squamous cell carcinoma [<a href="#rid66">66,67</a>]. Patients with XP are best treated with field-directed therapies, which include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical </strong><strong>fluorouracil</strong> – Topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> is the first-line field treatment for patients with XP [<a href="#rid63">63,68</a>]. A 1:1 combination of topical calcipotriene with fluorouracil shortens the treatment duration without decreasing efficacy. (See  <a class="medical medical_review" href="/z/d/html/5336.html" rel="external">"Treatment of actinic keratosis", section on 'Topical fluorouracil'</a> and  <a class="medical medical_review" href="/z/d/html/5336.html" rel="external">"Treatment of actinic keratosis", section on 'Topical fluorouracil plus calcipotriol'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imiquimod</strong> – <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">Imiquimod</a> is a topical immune response modifier approved for the treatment of actinic keratosis and superficial basal cell carcinoma. Imiquimod can be used as an alternative to topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> for the treatment of multiple actinic keratoses. (See  <a class="medical medical_review" href="/z/d/html/5336.html" rel="external">"Treatment of actinic keratosis", section on 'Imiquimod'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Photodynamic therapy</strong> – Photodynamic therapy involves the pretreatment of skin with a photosensitizing agent, which is preferentially absorbed by premalignant or malignant cells, followed by irradiation with a specific wavelength of light or exposure to daylight. This results in the death of the target cells. Photodynamic therapy has been described as a treatment for both actinic keratoses and small basal cell carcinomas in patients with XP [<a href="#rid69">69-72</a>]. (See  <a class="medical medical_review" href="/z/d/html/5336.html" rel="external">"Treatment of actinic keratosis", section on 'Photodynamic therapy'</a> and  <a class="medical medical_review" href="/z/d/html/13647.html" rel="external">"Photodynamic therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other modalities</strong> – Other effective modalities used to destroy actinic keratoses include cryotherapy with liquid nitrogen, <a class="drug drug_general" data-topicid="10296" href="/z/d/drug information/10296.html" rel="external">trichloroacetic acid</a> chemical peel, and ablative fractionated laser. (See  <a class="medical medical_review" href="/z/d/html/5336.html" rel="external">"Treatment of actinic keratosis", section on 'Liquid nitrogen cryosurgery'</a> and  <a class="medical medical_review" href="/z/d/html/5336.html" rel="external">"Treatment of actinic keratosis", section on 'Field ablation treatments'</a>.)</p><p></p><p class="headingAnchor" id="H963619566"><span class="h3">Nonmelanoma skin cancers</span></p><p class="headingAnchor" id="H2521196651"><span class="h4">Surgery</span><span class="headingEndMark"> — </span>Conventional wide local excision or Mohs micrographic surgery are the treatments of choice for skin cancers in patients with XP. Mohs micrographic surgery offers the highest cure rate with the lowest risk of recurrence and is preferred for cosmetically sensitive body sites or recurrent lesions [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/13713.html" rel="external">"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/13724.html" rel="external">"Treatment of basal cell carcinomas at high risk for recurrence"</a>.)</p><p class="headingAnchor" id="H2795618719"><span class="h4">Nonsurgical therapies</span><span class="headingEndMark"> — </span>Other therapies used to treat nonmelanoma skin cancer in patients with XP include cryosurgery, photodynamic therapy, <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> [<a href="#rid61">61,74-77</a>], and topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>. While these therapies may be inferior to surgical excision, there may be clinical scenarios in which skin-sparing options are reasonable alternatives. Imiquimod has been used successfully in patients with XP to treat basal cell carcinomas. Local skin inflammation and irritation are common, but ulceration, facial swelling, and rare systemic symptoms (eg, fever and malaise) have been reported. (See  <a class="medical medical_review" href="/z/d/html/5338.html" rel="external">"Treatment and prognosis of basal cell carcinoma at low risk of recurrence"</a> and  <a class="medical medical_review" href="/z/d/html/5339.html" rel="external">"Treatment and prognosis of low-risk cutaneous squamous cell carcinoma (cSCC)"</a>.)</p><p class="headingAnchor" id="H2485185891"><span class="h4">Systemic therapies</span><span class="headingEndMark"> — </span>Systemic therapies have been used in a few patients with XP with inoperable or metastatic nonmelanoma skin cancers. These treatments are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7619.html" rel="external">"Systemic treatment of advanced basal cell and cutaneous squamous cell carcinomas not amenable to local therapies"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hedgehog pathway inhibitors</strong> – In single case reports, the hedgehog pathway inhibitor <a class="drug drug_general" data-topicid="17142" href="/z/d/drug information/17142.html" rel="external">vismodegib</a> has been employed to manage multiple or unresectable basal cell carcinomas in patients with XP [<a href="#rid78">78,79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune checkpoint inhibitors</strong> – There are a few reports of the use of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, an anti-programmed cell death ligand 1 (PD-L1) checkpoint inhibitor, for the treatment of advanced skin cancers in patients with XP [<a href="#rid80">80-82</a>]. In one report, treatment with pembrolizumab and <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> for advanced cutaneous squamous cell carcinoma and melanoma in three patients also decreased the rates of new cutaneous malignancies [<a href="#rid83">83</a>]. However, these agents have significant adverse effects that may limit their use in patients with XP. (See  <a class="medical medical_review" href="/z/d/html/128565.html" rel="external">"Cutaneous immune-related adverse events associated with immune checkpoint inhibitors"</a> and  <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p></p><p class="headingAnchor" id="H3328302779"><span class="h3">Melanoma</span><span class="headingEndMark"> — </span>The staging system and management of melanoma in patients with XP is the same as for children and adults without XP. (See  <a class="medical medical_review" href="/z/d/html/101324.html" rel="external">"Melanoma in children", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/7620.html" rel="external">"Surgical management of primary cutaneous melanoma or melanoma at other unusual sites"</a> and  <a class="medical medical_review" href="/z/d/html/85841.html" rel="external">"Overview of the management of advanced cutaneous melanoma"</a>.)</p><p class="headingAnchor" id="H2024821922"><span class="h2">Management of extracutaneous manifestations</span></p><p class="headingAnchor" id="H3532901048"><span class="h3">Ocular management</span><span class="headingEndMark"> — </span>Patients should be followed up every three to six months with ophthalmology, and examinations should include assessment for eyelid and ocular surface tumors. UV-protective glasses or soft UV-protective contact lenses are recommended [<a href="#rid16">16</a>]. <a class="drug drug_general" data-topicid="10153" href="/z/d/drug information/10153.html" rel="external">Methylcellulose</a> eye drops may be used to protect against eye dryness. Corneal transplant or keratoplasty may improve vision in patients with severe keratitis. The use of keratoprosthesis or artificial cornea may be preferred to avoid immunosuppression, which can further increase the risk of skin cancers.</p><p>Ocular tumors are usually treated with excision or cryotherapy. Other modalities include combination of surgery and topical chemotherapy with <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">mitomycin</a> C [<a href="#rid84">84</a>], subconjunctival injections of interferon (IFN)-alpha-2b and topical mitomycin C [<a href="#rid85">85</a>], topical IFN-alpha-2b, and <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> eyedrops [<a href="#rid86">86</a>].</p><p class="headingAnchor" id="H3304797351"><span class="h3">Neurologic management</span><span class="headingEndMark"> — </span>There are no targeted treatments for the neurologic manifestations of XP. Treatments are primarily supportive and include speech, physical, and occupational therapy. Vision and hearing screening should be conducted at regular intervals starting early in life.</p><p class="headingAnchor" id="H1783687266"><span class="h1">INVESTIGATIONAL TREATMENTS</span></p><p class="headingAnchor" id="H2332635165"><span class="h2">Gene therapy</span><span class="headingEndMark"> — </span>Genetic techniques to improve DNA repair are the most promising approaches to the treatment of XP [<a href="#rid87">87,88</a>]. A retrovirus-based strategy to transduce the wild-type <em>XPC</em> gene into human XPC keratinocytes was used in an in vitro study using XPC keratinocytes without adverse effects (eg, oncogenic activation) [<a href="#rid89">89</a>]. The transcription activator-like effector nuclease (TALEN) technology was used to correct the frequent c.1643_1644delTG <em>XPC</em> mutation in XP cells [<a href="#rid90">90</a>].</p><p class="headingAnchor" id="H1174921398"><span class="h2">Topical agents</span></p><p class="headingAnchor" id="H2874567674"><span class="h3">T4 endonuclease</span><span class="headingEndMark"> — </span>Topical T4 endonuclease is a DNA repair enzyme that has been reported to decrease the rates of new basal cell carcinoma and precancerous actinic keratoses in patients with XP when applied topically to sun-exposed skin [<a href="#rid91">91</a>]. However, this agent has not been further investigated and is not available. </p><p class="headingAnchor" id="H1775595329"><span class="h3">Photolyase</span><span class="headingEndMark"> — </span>Several studies suggest that sunscreen containing photolyase may be effective in preventing actinic keratoses in patients at high risk [<a href="#rid92">92,93</a>]. Photolyases are enzymes expressed in bacteria, fungi, plants, and some animals (but not in placental mammals, including humans). Photolyases chemically reverse ultraviolet (UV)-induced DNA damage upon activation by visible light. Topical photolyases are approved as a medical device in Europe and are available over the counter in the United States.</p><p class="headingAnchor" id="H3781894312"><span class="h2">Agents targeting aging and senescence</span><span class="headingEndMark"> — </span>Animal models of XP recapitulate the cancer-prone phenotype but also suggest that there are aspects of accelerated aging (eg, the neurodegeneration and accelerated photoaging of the skin) [<a href="#rid94">94,95</a>]. There has been an effort to develop therapeutics that target fundamental mechanisms of aging [<a href="#rid96">96</a>]. These include agents that remove cells harboring DNA damage (ie, senescent cells), suppress inflammation or oxidative stress, improve metabolism, and replenish key metabolites that erode with aging [<a href="#rid97">97</a>]. These therapeutics significantly improve tissue homeostasis in mouse models [<a href="#rid98">98,99</a>]. However, whether these agents may mitigate disease progression in patients with XP has not been investigated.</p><p class="headingAnchor" id="H2657786792"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Patients with XP have a decreased life expectancy due to fatal skin malignancies, internal malignancies, and neurodegeneration. The reported mean lifespan is 29 and 37 years for those with and without neurodegeneration, respectively [<a href="#rid11">11</a>]. Patients with XP experience additional non-ultraviolet (UV)-induced causes of morbidity and mortality. Nearly 20 percent of patients with XP succumb to internal malignancies, including tumors of the central nervous system, head and neck cancers, and lung cancer [<a href="#rid11">11,32</a>].</p><p class="headingAnchor" id="H43649309"><span class="h1">GENETIC COUNSELING</span><span class="headingEndMark"> — </span>Genetic counseling is recommended for all families of patients with XP. For parents considering additional children, the risk of having another affected child is 25 percent, and the risk of a child being an asymptomatic carrier is 50 percent. Siblings should be tested to increase early diagnosis and implementation of ultraviolet (UV) protective measures.</p><p class="headingAnchor" id="H738212939"><span class="h1">RESOURCES AND SUPPORT GROUPS</span><span class="headingEndMark"> — </span>Several online resources and patient organizations can provide information and support for patients with XP and their families/caregivers.</p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Frarediseases.org%2F&amp;token=9E9IX7kiH9qRiTPgEvfhBeYjQOtPjl2OjGky4jLGFuLb510NH1k3XPz57jIaCL1j&amp;TOPIC_ID=15466" target="_blank">National Organization for Rare Diseases</a> provides a helpful overview of XP for health providers and families.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fxpfamilysupport.org%2F&amp;token=PIobsSQccGgmAKT6J9yiE16AeP72W2SHvNRNuMvrCQScnG9CZ6FBW7kL2OOefljL&amp;TOPIC_ID=15466" target="_blank">XP Family Support Group</a> is a United States group that provides information and resources, including ultraviolet (UV)-protecting hoods, gloves, and UV meters, to newly diagnosed families. They host a biannual family retreat and medical conference.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.xps.org%2F&amp;token=yOMMM%2F%2FSH49z5RmwYH%2Fopqetmy365wCNduvfPxHJeyg%3D&amp;TOPIC_ID=15466" target="_blank">Xeroderma Pigmentosum Society</a> is a United States support group for patients with XP and their parents/caregivers that includes Camp Sundown, a summer camp program oriented specifically for patients with photosensitive disorders and their families.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgeneticalliance.org.uk%2Fmember%2Fxp-support-group%2F&amp;token=L7xG8m%2BqlTUdp5Kd5LM5Isnp5s%2BGZO190qjQbiqtRXIsTwQgE91xyocXjCWByO%2Buiyd7gokiqet8eplqteNmXA%3D%3D&amp;TOPIC_ID=15466" target="_blank">XP Support Group</a> is a United Kingdom group that provides advice and support to patients with XP and their families.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.actionforxp.org%2F&amp;token=IQxLzDq4doJGUgaZgeIY0%2BhR7TB2SJeD5Zl4dPcDAIz7nehPMCJeg71MlRe58Zaw&amp;TOPIC_ID=15466" target="_blank">Action for XP</a> (formerly The Teddington Trust) is a United Kingdom charity that provides advice and support to patients with XP and their families.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Guy's and St. Thomas' Hospitals National Health Service Foundation Trust in the United Kingdom provides the only comprehensive evaluation and care center for patients with XP in the world, providing access to clinicians in all disciplines impacted by XP and Cockayne syndrome.</p><p></p><p class="headingAnchor" id="H2165968533"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118501.html" rel="external">"Society guideline links: Melanoma screening, prevention, diagnosis, and management"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/133179.html" rel="external">"Society guideline links: Cutaneous squamous cell carcinoma"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/141347.html" rel="external">"Society guideline links: Photosensitivity disorders (photodermatoses)"</a>.)</p><p class="headingAnchor" id="H1852377551"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and molecular pathogenesis</strong> – Xeroderma pigmentosum (XP) is an autosomal recessive disorder of DNA repair caused by inherited mutations in one of eight possible genes related to the repair or tolerance of ultraviolet (UV)-induced DNA damage and other helix-distorting DNA adducts. (See <a class="local">'Molecular genetics and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Clinical manifestations of XP include exaggerated, early sunburn reactions and progressive lentiginosis on exposed areas elicited by minimal UV exposure. Premature photoaging of the skin, telangiectasias, poikiloderma, xerosis, skin atrophy, and wrinkling are observed in childhood or teen years. Skin cancers occur early in life and are the leading cause of mortality. In some cases, depending on the complementation group and impact of specific mutations on the gene product function, intellectual impairment, progressive neurodegenerative disease, and/or the development of other malignancies may occur. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of XP is suspected in individuals presenting with one or more of the following (see <a class="local">'Clinical suspicion'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe sun sensitivity on minimal exposure</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Early skin freckling (before the age of two years)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Skin cancer during childhood</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Numerous skin cancers in early adulthood</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe photophobia with marked conjunctival injection and other ocular symptoms (eg, keratitis, corneal neovascularization and scarring)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neurologic symptoms (eg, loss of deep tendon reflexes, hearing loss)</p><p></p><p class="bulletIndent1">The definitive diagnosis of XP is made with genetic testing. (See <a class="local">'Genetic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Strict sun protection and avoidance, close clinical follow-up, and appropriate and early management of any premalignant and malignant skin lesions are the mainstays of treatment for patients with XP.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Photoprotection</strong> – Patients with XP require complete, strict photoprotection (including avoiding all outdoor and indoor UV light sources); protective clothing; eye protection/sunglasses; and application of broad-spectrum sunscreen to any exposed areas. Due to the increased risk for vitamin D deficiency associated with strict photoprotection, we suggest vitamin D supplementation for most patients with XP (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).<strong> </strong>(See  <a class="medical medical_review" href="/z/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surveillance for skin</strong> <strong>cancer</strong> – Regular skin and eye examination for early detection and treatment of skin cancer and premalignant lesions is recommended for all patients with XP. (See <a class="local">'Photoprotection strategies'</a> above and <a class="local">'Skin cancer surveillance'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of actinic keratosis</strong> – Actinic keratoses are best treated with field-directed therapies, including topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a>, and photodynamic therapy. (See <a class="local">'Actinic keratosis'</a> above and  <a class="medical medical_review" href="/z/d/html/5336.html" rel="external">"Treatment of actinic keratosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of nonmelanoma skin cancers</strong> – Wide local excision and Mohs surgery are first-line treatments for nonmelanoma skin cancers. Alternative therapies, including cryosurgery, <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a>, and topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, may be used for low-risk or superficial tumors. (See <a class="local">'Nonmelanoma skin cancers'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of melanoma</strong> – The treatment of melanoma in patients with XP is the same as for children and adults without XP. (See  <a class="medical medical_review" href="/z/d/html/101324.html" rel="external">"Melanoma in children", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/7620.html" rel="external">"Surgical management of primary cutaneous melanoma or melanoma at other unusual sites"</a> and  <a class="medical medical_review" href="/z/d/html/85841.html" rel="external">"Overview of the management of advanced cutaneous melanoma"</a>.)</p><p></p><p class="headingAnchor" id="H2344579613"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Lawrence F Eichenfield, MD, and Catherine Gupta Warner, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kleijer WJ, Laugel V, Berneburg M, et al. Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. DNA Repair (Amst) 2008; 7:744.</a></li><li><a class="nounderline abstract_t">Hirai Y, Kodama Y, Moriwaki S, et al. Heterozygous individuals bearing a founder mutation in the XPA DNA repair gene comprise nearly 1% of the Japanese population. Mutat Res 2006; 601:171.</a></li><li><a class="nounderline abstract_t">Fassihi H, Sethi M, Fawcett H, et al. Deep phenotyping of 89 xeroderma pigmentosum patients reveals unexpected heterogeneity dependent on the precise molecular defect. Proc Natl Acad Sci U S A 2016; 113:E1236.</a></li><li><a class="nounderline abstract_t">Nawal W, Ullah A, Ullah U, et al. Loss of Function Variants in the XPC Causes Severe Xeroderma Pigmentosum in Three Large Consanguineous Families. Klin Padiatr 2022; 234:123.</a></li><li><a class="nounderline abstract_t">Rabie E, Amr K, Zada S, et al. Clinical and Mutational Spectrum of Xeroderma Pigmentosum in Egypt: Identification of Six Novel Mutations and Implications for Ancestral Origins. Genes (Basel) 2021; 12.</a></li><li><a class="nounderline abstract_t">Romdhane L, Kefi R, Azaiez H, et al. Founder mutations in Tunisia: implications for diagnosis in North Africa and Middle East. Orphanet J Rare Dis 2012; 7:52.</a></li><li><a class="nounderline abstract_t">Doubaj Y, Laarabi FZ, Elalaoui SC, et al. Carrier frequency of the recurrent mutation c.1643_1644delTG in the XPC gene and birth prevalence of the xeroderma pigmentosum in Morocco. J Dermatol 2012; 39:382.</a></li><li><a class="nounderline abstract_t">Black JO. Xeroderma Pigmentosum. Head Neck Pathol 2016; 10:139.</a></li><li><a class="nounderline abstract_t">DiGiovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum. J Invest Dermatol 2012; 132:785.</a></li><li><a class="nounderline abstract_t">Krasikova Y, Rechkunova N, Lavrik O. Nucleotide Excision Repair: From Molecular Defects to Neurological Abnormalities. Int J Mol Sci 2021; 22.</a></li><li><a class="nounderline abstract_t">Bradford PT, Goldstein AM, Tamura D, et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet 2011; 48:168.</a></li><li><a class="nounderline abstract_t">Anttinen A, Koulu L, Nikoskelainen E, et al. Neurological symptoms and natural course of xeroderma pigmentosum. Brain 2008; 131:1979.</a></li><li><a class="nounderline abstract_t">Niedernhofer LJ, Bohr VA, Sander M, Kraemer KH. Xeroderma pigmentosum and other diseases of human premature aging and DNA repair: molecules to patients. Mech Ageing Dev 2011; 132:340.</a></li><li><a class="nounderline abstract_t">Abeti R, Zeitlberger A, Peelo C, et al. Xeroderma pigmentosum: overview of pharmacology and novel therapeutic strategies for neurological symptoms. Br J Pharmacol 2019; 176:4293.</a></li><li><a class="nounderline abstract_t">Sethi M, Lehmann AR, Fawcett H, et al. Patients with xeroderma pigmentosum complementation groups C, E and V do not have abnormal sunburn reactions. Br J Dermatol 2013; 169:1279.</a></li><li><a class="nounderline abstract_t">Leung AK, Barankin B, Lam JM, et al. Xeroderma pigmentosum: an updated review. Drugs Context 2022; 11.</a></li><li><a class="nounderline abstract_t">Best DL, Spresser W, Shivers P, et al. Squamous Cell Carcinoma of the Tongue in Young Patients: A Case Series and Literature Review. J Oral Maxillofac Surg 2021; 79:1270.</a></li><li><a class="nounderline abstract_t">Huet-Lamy P, Dereure O, Degavre B, et al. [Carcinoma of the tongue in xeroderma pigmentosum]. Ann Dermatol Venereol 1992; 119:980.</a></li><li><a class="nounderline abstract_t">Chidzonga MM, Mahomva L, Makunike-Mutasa R, Masanganise R. Xeroderma pigmentosum: a retrospective case series in Zimbabwe. J Oral Maxillofac Surg 2009; 67:22.</a></li><li><a class="nounderline abstract_t">Olson MT, Puttgen KB, Westra WH. Angiosarcoma arising from the tongue of an 11-year-old girl with xeroderma pigmentosum. Head Neck Pathol 2012; 6:255.</a></li><li><a class="nounderline abstract_t">Bologna SB, Harumi Nakajima Teshima T, Lourenço SV, Nico MM. An atrophic, telangiectatic patch at the distal border of the tongue: a mucous membrane manifestation of xeroderma pigmentosum. Pediatr Dermatol 2014; 31:e38.</a></li><li><a class="nounderline abstract_t">Lim R, Sethi M, Morley AMS. Ophthalmic Manifestations of Xeroderma Pigmentosum: A Perspective from the United Kingdom. Ophthalmology 2017; 124:1652.</a></li><li><a class="nounderline abstract_t">Brooks BP, Thompson AH, Bishop RJ, et al. Ocular manifestations of xeroderma pigmentosum: long-term follow-up highlights the role of DNA repair in protection from sun damage. Ophthalmology 2013; 120:1324.</a></li><li><a class="nounderline abstract_t">Totonchy MB, Tamura D, Pantell MS, et al. Auditory analysis of xeroderma pigmentosum 1971-2012: hearing function, sun sensitivity and DNA repair predict neurological degeneration. Brain 2013; 136:194.</a></li><li><a class="nounderline abstract_t">Garcia-Moreno H, Langbehn DR, Abiona A, et al. Neurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression. Brain 2023; 146:5044.</a></li><li><a class="nounderline abstract_t">Macedo LT, Costa EFD, Carvalho BF, et al. Association of Clinical Aspects and Genetic Variants with the Severity of Cisplatin-Induced Ototoxicity in Head and Neck Squamous Cell Carcinoma: A Prospective Cohort Study. Cancers (Basel) 2023; 15.</a></li><li><a class="nounderline abstract_t">Rizza ERH, DiGiovanna JJ, Khan SG, et al. Xeroderma Pigmentosum: A Model for Human Premature Aging. J Invest Dermatol 2021; 141:976.</a></li><li><a class="nounderline abstract_t">Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987; 123:241.</a></li><li><a class="nounderline abstract_t">Lai JP, Liu YC, Alimchandani M, et al. The influence of DNA repair on neurological degeneration, cachexia, skin cancer and internal neoplasms: autopsy report of four xeroderma pigmentosum patients (XP-A, XP-C and XP-D). Acta Neuropathol Commun 2013; 1:4.</a></li><li><a class="nounderline abstract_t">Nikolaev S, Yurchenko AA, Sarasin A. Increased risk of internal tumors in DNA repair-deficient xeroderma pigmentosum patients: analysis of four international cohorts. Orphanet J Rare Dis 2022; 17:104.</a></li><li><a class="nounderline abstract_t">Sarasin A, Quentin S, Droin N, et al. Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum. Blood 2019; 133:2718.</a></li><li><a class="nounderline abstract_t">Sibar S, Findikcioglu K, Erdal AI, et al. Technical Aspects and Difficulties in the Management of Head and Neck Cutaneous Malignancies in Xeroderma Pigmentosum. Arch Plast Surg 2016; 43:344.</a></li><li><a class="nounderline abstract_t">Su J, Zhu Y, Dai B, et al. XPG Asp1104His polymorphism increases colorectal cancer risk especially in Asians. Am J Transl Res 2019; 11:1020.</a></li><li><a class="nounderline abstract_t">Wang L, Wang LL, Shang D, et al. Gene polymorphism of DNA repair gene X-ray repair cross complementing group 1 and xeroderma pigmentosum group D and environment interaction in non-small-cell lung cancer for Chinese nonsmoking female patients. Kaohsiung J Med Sci 2019; 35:39.</a></li><li><a class="nounderline abstract_t">Kouatcheu SD, Marko J, Tamura D, et al. Thyroid nodules in xeroderma pigmentosum patients: a feature of premature aging. J Endocrinol Invest 2021; 44:1475.</a></li><li><a class="nounderline abstract_t">Merideth M, Tamura D, Angra D, et al. Reproductive Health in Xeroderma Pigmentosum: Features of Premature Aging. Obstet Gynecol 2019; 134:814.</a></li><li class="breakAll">Kraemer KH, DiGiovanna JJ, Tamura D. Xeroderma pigmentosum. In: GeneReviews, Adam MP, Mirzaa GM, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.</li><li><a class="nounderline abstract_t">Moriwaki S, Kanda F, Hayashi M, et al. Xeroderma pigmentosum clinical practice guidelines. J Dermatol 2017; 44:1087.</a></li><li><a class="nounderline abstract_t">Limsirichaikul S, Niimi A, Fawcett H, et al. A rapid non-radioactive technique for measurement of repair synthesis in primary human fibroblasts by incorporation of ethynyl deoxyuridine (EdU). Nucleic Acids Res 2009; 37:e31.</a></li><li><a class="nounderline abstract_t">García-Carmona JA, Yousefzadeh MJ, Alarcón-Soldevilla F, et al. Case Report: Identification of a Heterozygous XPA c.553C&gt;T Mutation Causing Neurological Impairment in a Case of Xeroderma Pigmentosum Complementation Group A. Front Genet 2021; 12:717361.</a></li><li><a class="nounderline abstract_t">Kleijer WJ, van der Sterre ML, Garritsen VH, et al. Prenatal diagnosis of xeroderma pigmentosum and trichothiodystrophy in 76 pregnancies at risk. Prenat Diagn 2007; 27:1133.</a></li><li><a class="nounderline abstract_t">Patel R. Genetic Diagnosis of Cockayne Syndrome. Pediatr Neurol Briefs 2020; 34:9.</a></li><li><a class="nounderline abstract_t">Maguina M, Kang PB, Tsai AC, Pacak CA. Peripheral neuropathies associated with DNA repair disorders. Muscle Nerve 2023; 67:101.</a></li><li><a class="nounderline abstract_t">Wilson BT, Stark Z, Sutton RE, et al. The Cockayne Syndrome Natural History (CoSyNH) study: clinical findings in 102 individuals and recommendations for care. Genet Med 2016; 18:483.</a></li><li><a class="nounderline abstract_t">Vermeulen W, Jaeken J, Jaspers NG, et al. Xeroderma pigmentosum complementation group G associated with Cockayne syndrome. Am J Hum Genet 1993; 53:185.</a></li><li><a class="nounderline abstract_t">Atkinson EC, Thiara D, Tamura D, et al. Growth and nutrition in children with trichothiodystrophy. J Pediatr Gastroenterol Nutr 2014; 59:458.</a></li><li><a class="nounderline abstract_t">Theil AF, Botta E, Raams A, et al. Bi-allelic TARS Mutations Are Associated with Brittle Hair Phenotype. Am J Hum Genet 2019; 105:434.</a></li><li><a class="nounderline abstract_t">Yew YW, Giordano CN, Spivak G, Lim HW. Understanding photodermatoses associated with defective DNA repair: Photosensitive syndromes without associated cancer predisposition. J Am Acad Dermatol 2016; 75:873.</a></li><li><a class="nounderline abstract_t">Spivak G. UV-sensitive syndrome. Mutat Res 2005; 577:162.</a></li><li><a class="nounderline abstract_t">Ijaz A, Wolf S, Mandukhail SR, et al. UV-sensitive syndrome: Whole exome sequencing identified a nonsense mutation in the gene UVSSA in two consanguineous pedigrees from Pakistan. J Dermatol Sci 2019; 95:113.</a></li><li><a class="nounderline abstract_t">Balwani M. Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management. Mol Genet Metab 2019; 128:298.</a></li><li><a class="nounderline abstract_t">Arora H, Chacon AH, Choudhary S, et al. Bloom syndrome. Int J Dermatol 2014; 53:798.</a></li><li class="breakAll">Wang LL, Plon SE. Rothmund-Thomson syndrome. In: GeneReviews, Adam MP, Mirzaa GM, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.</li><li><a class="nounderline abstract_t">Haijes HA, Prinsen HCMT, de Sain-van der Velden MGM, et al. Accurate discrimination of Hartnup disorder from other aminoacidurias using a diagnostic ratio. Mol Genet Metab Rep 2020; 22:100551.</a></li><li><a class="nounderline abstract_t">Sarkany RPE, Canfield M, Morgan M, et al. Ultraviolet radiation exposure to the face in patients with xeroderma pigmentosum and healthy controls: applying a novel methodology to define photoprotection behaviour. Br J Dermatol 2022; 186:713.</a></li><li><a class="nounderline abstract_t">Walburn J, Canfield M, Norton S, et al. Psychological correlates of adherence to photoprotection in a rare disease: International survey of people with Xeroderma Pigmentosum. Br J Health Psychol 2019; 24:668.</a></li><li><a class="nounderline abstract_t">Tamura D, DiGiovanna JJ, Khan SG, Kraemer KH. Living with xeroderma pigmentosum: comprehensive photoprotection for highly photosensitive patients. Photodermatol Photoimmunol Photomed 2014; 30:146.</a></li><li><a class="nounderline abstract_t">Weinstock MA, Thwin SS, Siegel JA, et al. Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial. JAMA Dermatol 2018; 154:167.</a></li><li><a class="nounderline abstract_t">Neugebauer R, Su KA, Zhu Z, et al. Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study. J Am Acad Dermatol 2019; 80:998.</a></li><li><a class="nounderline abstract_t">Kim J, Savory SA, Demehri S, Gill JG. Prevention of Skin Cancers With Topical Calcipotriol and Fluorouracil in Patients With Xeroderma Pigmentosum. JAMA Dermatol 2023; 159:226.</a></li><li><a class="nounderline abstract_t">Rocha LKFL, Ferreira P, Gianotti MA, et al. Imiquimod chemoprophylaxis for field cancerization in xeroderma pigmentosum patients-A prospective study. Australas J Dermatol 2023; 64:435.</a></li><li><a class="nounderline abstract_t">Kraemer KH, DiGiovanna JJ, Moshell AN, et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318:1633.</a></li><li><a class="nounderline abstract_t">Kraemer KH, DiGiovanna JJ, Peck GL. Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol 1992; 19:715.</a></li><li><a class="nounderline abstract_t">Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med 2015; 373:1618.</a></li><li><a class="nounderline abstract_t">Allen NC, Martin AJ, Snaidr VA, et al. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. N Engl J Med 2023; 388:804.</a></li><li><a class="nounderline abstract_t">Worley B, Harikumar V, Reynolds K, et al. Treatment of actinic keratosis: a systematic review. Arch Dermatol Res 2023; 315:1099.</a></li><li><a class="nounderline abstract_t">Ezzedine K, Painchault C, Brignone M. Systematic Literature Review and Network Meta-analysis of the Efficacy and Acceptability of Interventions in Actinic Keratoses. Acta Derm Venereol 2021; 101:adv00358.</a></li><li><a class="nounderline abstract_t">Boussen H, Zwik J, Mili-Boussen I, et al. [Therapeutic results of 5-fluorouracil in multiple and unresectable facial carcinoma secondary to xeroderma pigmentosum]. Therapie 2001; 56:751.</a></li><li><a class="nounderline abstract_t">Cai H, Yang QQ, Ma C, et al. Photodynamic therapy in the treatment of xeroderma pigmentosum: A case report. Photodiagnosis Photodyn Ther 2020; 30:101761.</a></li><li><a class="nounderline abstract_t">Larson DM, Cunningham BB. Photodynamic therapy in a teenage girl with xeroderma pigmentosum type C. Pediatr Dermatol 2012; 29:373.</a></li><li><a class="nounderline abstract_t">Fernández-Guarino M, Mavura D, Fernández-González P, et al. Daylight photodynamic therapy is an option for the treatment of actinic keratosis in patients with xeroderma pigmentosum in Africa. Photodiagnosis Photodyn Ther 2020; 29:101631.</a></li><li><a class="nounderline abstract_t">Zheng J, Liu W, Zhou Z, et al. Successful treatment of non-melanoma skin cancer in three patients with Xeroderma Pigmentosum by modified ALA-PDT. Photodiagnosis Photodyn Ther 2023; 43:103694.</a></li><li><a class="nounderline abstract_t">Greig A, Aloni K, Orchard G, et al. Treatment of multiple facial basal cell carcinomas in a child with xeroderma pigmentosum complementation group C with Mohs micrographic surgery. Br J Dermatol 2021; 184:e4.</a></li><li><a class="nounderline abstract_t">Yang JQ, Chen XY, Engle MY, Wang JY. Multiple facial basal cell carcinomas in xeroderma pigmentosum treated with topical imiquimod 5% cream. Dermatol Ther 2015; 28:243.</a></li><li><a class="nounderline abstract_t">Nagore E, Sevila A, Sanmartin O, et al. Excellent response of basal cell carcinomas and pigmentary changes in xeroderma pigmentosum to imiquimod 5% cream. Br J Dermatol 2003; 149:858.</a></li><li><a class="nounderline abstract_t">Malhotra AK, Gupta S, Khaitan BK, Verma KK. Multiple basal cell carcinomas in xeroderma pigmentosum treated with imiquimod 5% cream. Pediatr Dermatol 2008; 25:488.</a></li><li><a class="nounderline abstract_t">Nijsten T, Lapière K, Lambert J. A patient with xeroderma pigmentosum treated with imiquimod 5% cream. J Am Acad Dermatol 2005; 52:170.</a></li><li><a class="nounderline abstract_t">Soura E, Plaka M, Dessinioti C, et al. Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum. Pediatr Dermatol 2018; 35:e334.</a></li><li><a class="nounderline abstract_t">Fife D, Laitinen MA, Myers DJ, Landsteiner PB. Vismodegib Therapy for Basal Cell Carcinoma in an 8-Year-Old Chinese Boy with Xeroderma Pigmentosum. Pediatr Dermatol 2017; 34:163.</a></li><li><a class="nounderline abstract_t">Salomon G, Maza A, Boulinguez S, et al. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum. Br J Dermatol 2018; 178:1199.</a></li><li><a class="nounderline abstract_t">Chambon F, Osdoit S, Bagny K, et al. Dramatic response to nivolumab in xeroderma pigmentosum skin tumor. Pediatr Blood Cancer 2018; 65.</a></li><li><a class="nounderline abstract_t">Hauschild A, Eichstaedt J, Möbus L, et al. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab. Eur J Cancer 2017; 77:84.</a></li><li><a class="nounderline abstract_t">Ameri AH, Mooradian MJ, Emerick KS, et al. Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum. Br J Dermatol 2019; 181:1095.</a></li><li><a class="nounderline abstract_t">Kalamkar C, Radke N, Mukherjee A, Radke S. Xeroderma pigmentosum with bilateral ocular surface squamous neoplasia and review of the literature. BMJ Case Rep 2016; 2016.</a></li><li><a class="nounderline abstract_t">Dirar QS, Musalem HM, Al-Hazzaa SAF, et al. Effect of Pegylated Interferon and Mitomycin C on Ocular Surface Squamous Neoplasia in Xeroderma Pigmentosum: A Case Series. Am J Case Rep 2020; 21:e921301.</a></li><li><a class="nounderline abstract_t">Venkateswaran N, Mercado C, Galor A, Karp CL. Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia. Am J Ophthalmol 2019; 199:216.</a></li><li><a class="nounderline abstract_t">Dupuy A, Sarasin A. DNA damage and gene therapy of xeroderma pigmentosum, a human DNA repair-deficient disease. Mutat Res 2015; 776:2.</a></li><li><a class="nounderline abstract_t">Goncalves-Maia M, Magnaldo T. Genetic therapy of xeroderma pigmentosum: Analysis of strategies and translation. Expert Opin Orphan Drugs 2017; 5:5.</a></li><li><a class="nounderline abstract_t">Warrick E, Garcia M, Chagnoleau C, et al. Preclinical corrective gene transfer in xeroderma pigmentosum human skin stem cells. Mol Ther 2012; 20:798.</a></li><li><a class="nounderline abstract_t">Dupuy A, Valton J, Leduc S, et al. Targeted gene therapy of xeroderma pigmentosum cells using meganuclease and TALEN. PLoS One 2013; 8:e78678.</a></li><li><a class="nounderline abstract_t">Yarosh D, Klein J, O'Connor A, et al. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet 2001; 357:926.</a></li><li><a class="nounderline abstract_t">Moscarella E, Argenziano G, Longo C, Aladren S. Management of cancerization field with a medical device containing photolyase: a randomized, double-blind, parallel-group pilot study. J Eur Acad Dermatol Venereol 2017; 31:e401.</a></li><li><a class="nounderline abstract_t">Eibenschutz L, Silipo V, De Simone P, et al. A 9-month, randomized, assessor-blinded, parallel-group study to evaluate clinical effects of film-forming medical devices containing photolyase and sun filters in the treatment of field cancerization compared with sunscreen in patients after successful photodynamic therapy for actinic keratosis. Br J Dermatol 2016; 175:1391.</a></li><li><a class="nounderline abstract_t">Naylor EC, Watson RE, Sherratt MJ. Molecular aspects of skin ageing. Maturitas 2011; 69:249.</a></li><li><a class="nounderline abstract_t">Orso F, Jäger R, Calogero RA, et al. AP-2alpha regulates migration of GN-11 neurons via a specific genetic programme involving the Axl receptor tyrosine kinase. BMC Biol 2009; 7:25.</a></li><li><a class="nounderline abstract_t">Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell 2014; 159:709.</a></li><li><a class="nounderline abstract_t">López-Otín C, Blasco MA, Partridge L, et al. Hallmarks of aging: An expanding universe. Cell 2023; 186:243.</a></li><li><a class="nounderline abstract_t">Fuhrmann-Stroissnigg H, Niedernhofer LJ, Robbins PD. Hsp90 inhibitors as senolytic drugs to extend healthy aging. Cell Cycle 2018; 17:1048.</a></li><li><a class="nounderline abstract_t">Tilstra JS, Robinson AR, Wang J, et al. NF-κB inhibition delays DNA damage-induced senescence and aging in mice. J Clin Invest 2012; 122:2601.</a></li></ol></div><div id="topicVersionRevision">Topic 15466 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18329345" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16905156" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Heterozygous individuals bearing a founder mutation in the XPA DNA repair gene comprise nearly 1% of the Japanese population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26884178" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Deep phenotyping of 89 xeroderma pigmentosum patients reveals unexpected heterogeneity dependent on the precise molecular defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34544175" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Loss of Function Variants in the XPC Causes Severe Xeroderma Pigmentosum in Three Large Consanguineous Families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33672602" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical and Mutational Spectrum of Xeroderma Pigmentosum in Egypt: Identification of Six Novel Mutations and Implications for Ancestral Origins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22908982" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Founder mutations in Tunisia: implications for diagnosis in North Africa and Middle East.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22211393" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Carrier frequency of the recurrent mutation c.1643_1644delTG in the XPC gene and birth prevalence of the xeroderma pigmentosum in Morocco.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26975629" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Xeroderma Pigmentosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22217736" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Shining a light on xeroderma pigmentosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34207557" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Nucleotide Excision Repair: From Molecular Defects to Neurological Abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21097776" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18567921" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Neurological symptoms and natural course of xeroderma pigmentosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21708183" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Xeroderma pigmentosum and other diseases of human premature aging and DNA repair: molecules to patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30499105" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Xeroderma pigmentosum: overview of pharmacology and novel therapeutic strategies for neurological symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23889214" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Patients with xeroderma pigmentosum complementation groups C, E and V do not have abnormal sunburn reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35520754" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Xeroderma pigmentosum: an updated review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33450194" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Squamous Cell Carcinoma of the Tongue in Young Patients: A Case Series and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1304692" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : [Carcinoma of the tongue in xeroderma pigmentosum].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19070744" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Xeroderma pigmentosum: a retrospective case series in Zimbabwe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21987224" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Angiosarcoma arising from the tongue of an 11-year-old girl with xeroderma pigmentosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24456184" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : An atrophic, telangiectatic patch at the distal border of the tongue: a mucous membrane manifestation of xeroderma pigmentosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28554534" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ophthalmic Manifestations of Xeroderma Pigmentosum: A Perspective from the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23601806" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ocular manifestations of xeroderma pigmentosum: long-term follow-up highlights the role of DNA repair in protection from sun damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23365097" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Auditory analysis of xeroderma pigmentosum 1971-2012: hearing function, sun sensitivity and DNA repair predict neurological degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38040034" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Neurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36980643" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Association of Clinical Aspects and Genetic Variants with the Severity of Cisplatin-Induced Ototoxicity in Head and Neck Squamous Cell Carcinoma: A Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33436302" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Xeroderma Pigmentosum: A Model for Human Premature Aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3545087" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24252196" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The influence of DNA repair on neurological degeneration, cachexia, skin cancer and internal neoplasms: autopsy report of four xeroderma pigmentosum patients (XP-A, XP-C and XP-D).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35246173" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Increased risk of internal tumors in DNA repair-deficient xeroderma pigmentosum patients: analysis of four international cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30914417" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27462567" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Technical Aspects and Difficulties in the Management of Head and Neck Cutaneous Malignancies in Xeroderma Pigmentosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30899401" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : XPG Asp1104His polymorphism increases colorectal cancer risk especially in Asians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30844146" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Gene polymorphism of DNA repair gene X-ray repair cross complementing group 1 and xeroderma pigmentosum group D and environment interaction in non-small-cell lung cancer for Chinese nonsmoking female patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33155181" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Thyroid nodules in xeroderma pigmentosum patients: a feature of premature aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31503159" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Reproductive Health in Xeroderma Pigmentosum: Features of Premature Aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31503159" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Reproductive Health in Xeroderma Pigmentosum: Features of Premature Aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28771907" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Xeroderma pigmentosum clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179371" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A rapid non-radioactive technique for measurement of repair synthesis in primary human fibroblasts by incorporation of ethynyl deoxyuridine (EdU).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34484303" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Case Report: Identification of a Heterozygous XPA c.553C&gt;T Mutation Causing Neurological Impairment in a Case of Xeroderma Pigmentosum Complementation Group A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17880036" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prenatal diagnosis of xeroderma pigmentosum and trichothiodystrophy in 76 pregnancies at risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33281429" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Genetic Diagnosis of Cockayne Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36190439" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Peripheral neuropathies associated with DNA repair disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26204423" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The Cockayne Syndrome Natural History (CoSyNH) study: clinical findings in 102 individuals and recommendations for care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8317483" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Xeroderma pigmentosum complementation group G associated with Cockayne syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24918982" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Growth and nutrition in children with trichothiodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31374204" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Bi-allelic TARS Mutations Are Associated with Brittle Hair Phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27745642" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Understanding photodermatoses associated with defective DNA repair: Photosensitive syndromes without associated cancer predisposition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15916784" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : UV-sensitive syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31421932" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : UV-sensitive syndrome: Whole exome sequencing identified a nonsense mutation in the gene UVSSA in two consanguineous pedigrees from Pakistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30704898" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24602044" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Bloom syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24602044" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Bloom syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31908951" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Accurate discrimination of Hartnup disorder from other aminoacidurias using a diagnostic ratio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34783007" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Ultraviolet radiation exposure to the face in patients with xeroderma pigmentosum and healthy controls: applying a novel methodology to define photoprotection behaviour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31183946" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Psychological correlates of adherence to photoprotection in a rare disease: International survey of people with Xeroderma Pigmentosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24417420" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Living with xeroderma pigmentosum: comprehensive photoprotection for highly photosensitive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29299592" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30458208" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36542363" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Prevention of Skin Cancers With Topical Calcipotriol and Fluorouracil in Patients With Xeroderma Pigmentosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37052254" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Imiquimod chemoprophylaxis for field cancerization in xeroderma pigmentosum patients-A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3287161" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1293159" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Chemoprevention of skin cancer in xeroderma pigmentosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26488693" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36856616" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36454335" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Treatment of actinic keratosis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33170301" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Systematic Literature Review and Network Meta-analysis of the Efficacy and Acceptability of Interventions in Actinic Keratoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11878102" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : [Therapeutic results of 5-fluorouracil in multiple and unresectable facial carcinoma secondary to xeroderma pigmentosum].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32283311" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Photodynamic therapy in the treatment of xeroderma pigmentosum: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22277026" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Photodynamic therapy in a teenage girl with xeroderma pigmentosum type C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31904551" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Daylight photodynamic therapy is an option for the treatment of actinic keratosis in patients with xeroderma pigmentosum in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37422200" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Successful treatment of non-melanoma skin cancer in three patients with Xeroderma Pigmentosum by modified ALA-PDT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33325539" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Treatment of multiple facial basal cell carcinomas in a child with xeroderma pigmentosum complementation group C with Mohs micrographic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25754701" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Multiple facial basal cell carcinomas in xeroderma pigmentosum treated with topical imiquimod 5% cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616381" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Excellent response of basal cell carcinomas and pigmentary changes in xeroderma pigmentosum to imiquimod 5% cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18789101" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Multiple basal cell carcinomas in xeroderma pigmentosum treated with imiquimod 5% cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15627108" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A patient with xeroderma pigmentosum treated with imiquimod 5% cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30178564" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28297142" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Vismodegib Therapy for Basal Cell Carcinoma in an 8-Year-Old Chinese Boy with Xeroderma Pigmentosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29274233" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28988442" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Dramatic response to nivolumab in xeroderma pigmentosum skin tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28365530" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31102460" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27166000" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Xeroderma pigmentosum with bilateral ocular surface squamous neoplasia and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32251268" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effect of Pegylated Interferon and Mitomycin C on Ocular Surface Squamous Neoplasia in Xeroderma Pigmentosum: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30471241" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26255934" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : DNA damage and gene therapy of xeroderma pigmentosum, a human DNA repair-deficient disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Genetic therapy of xeroderma pigmentosum: Analysis of strategies and translation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22068429" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Preclinical corrective gene transfer in xeroderma pigmentosum human skin stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24236034" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Targeted gene therapy of xeroderma pigmentosum cells using meganuclease and TALEN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11289350" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28294419" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Management of cancerization field with a medical device containing photolyase: a randomized, double-blind, parallel-group pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27167413" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A 9-month, randomized, assessor-blinded, parallel-group study to evaluate clinical effects of film-forming medical devices containing photolyase and sun filters in the treatment of field cancerization compared with sunscreen in patients after successful photodynamic therapy for actinic keratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21612880" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Molecular aspects of skin ageing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19463168" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : AP-2alpha regulates migration of GN-11 neurons via a specific genetic programme involving the Axl receptor tyrosine kinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25417146" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Geroscience: linking aging to chronic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36599349" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Hallmarks of aging: An expanding universe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29886783" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Hsp90 inhibitors as senolytic drugs to extend healthy aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22706308" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : NF-κB inhibition delays DNA damage-induced senescence and aging in mice.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
